Connect Biopharmaceuticals

company

About

Connect Biopharma is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation.

  • 1 - 10

Details

Last Funding Type
Seed
Last Funding Money Raised
$5M
Industries
Biotechnology,Clinical Trials,Health Care,Medical,Therapeutics
Founded date
Jan 1, 2012
Number Of Employee
1 - 10
Operating Status
Active

Connect Biopharmaceuticals is a clinical-stage company that discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. They identify and advance our drug candidates through in-house discovery and in-licensing while leveraging qualified CROs for further development. The company successfully completed a phase I clinical trial study on our leading program CBP-307, a novel and selective second-generation S1P1 (a G-protein coupled receptor -GPCR) modulator for the treatment of a range of autoimmune disorders, including multiple sclerosis, inflammatory bowel disease, and psoriasis.

Connect Biopharmaceuticals currently conducting two phases 2 clinical studies in patients with ulcerative colitis and Crohn's disease with their lead drug candidate CBP-307. It also concluding a phase 1 study of our second drug candidate CBP-201 in healthy subjects, with a phase 1b study in atopic dermatitis patients expected to commence in Q1, 2019.

Connect Biopharmaceuticals was founded in 2012 and is headquartered in Taichang, China.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$120M
Connect Biopharmaceuticals has raised a total of $120M in funding over 2 rounds. Their latest funding was raised on Aug 24, 2020 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 24, 2020 Series C $115M 1 Detail
Nov 1, 2016 Seed $5M 2 Detail

Investors

Number of Lead Investors
Number of Investors
3
Connect Biopharmaceuticals is funded by 3 investors. Lilly Asia Ventures and XinYue Equity are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures Series C
XinYue Equity Seed
Anlongmed Fund Seed